Channels - Durability of the Humoral Response to MPXV Infection :: FRELIP Discovery

Similar Items: Durability of the Humoral Response to MPXV Infection

Quick Look
A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence
Quick Look
Recurrent zosteriform herpes simplex infection in a woman
Quick Look
Towards Elimination of Sexually Transmitted Infections: Research Developments and Vaccine Uptake
Quick Look
ABCB1 Polymorphism in HIV-Infected Individuals Taking Antiretroviral Drugs
Quick Look
Calprotectin Levels in HIV-Infected Patients: Correlations With Disease Progression and Intestinal Inflammation
Quick Look
Migratory Movements and Its Effect on the Epidemiology and Clinical Profile of HIV Infection in Quito, Ecuador
Quick Look
Potential Use of Neisseria meningitidis Serogroup B Vaccines to Prevent Neisseria gonorrhoeae Infection: Epidemiological Considerations
Quick Look
Incidence and Predictors of Opportunistic Infection Among People Living With HIV in Ethiopia: A Systematic Review and Meta-Analysis
Quick Look
A Response to “The Inverse Koebner Phenomenon in Cutaneous T‐Cell Lymphomas”
Quick Look
Incidence of Skin Infections in Patients with Atopic Dermatitis Treated with Topical Medications: A Cohort Study Using Japanese Claims Data
Quick Look
New Tuberculosis Infection and Reactivation of Tuberculosis in Patients with Psoriasis or Psoriatic Arthritis Receiving IL-23 Inhibitors: A Systematic Literature Review
Quick Look
Epidermolytic ichthyosis, palmoplantar keratoderma with keratin 10 mutation and response to oral retinoid
Quick Look
Remote Monitoring of Cryosurgery Response Using a Smartphone App: Prospective Study
Quick Look
Analysis of Predictors of Response Degree to Omalizumab in 124 Patients with Chronic Spontaneous Urticaria
Quick Look
Evaluating the Role of Disease Duration in Systemic Therapy Response Among Patients with Moderate-to-Severe Psoriasis
Quick Look
BIKSWITCH Study: Effectiveness and Safety of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Therapies Not Based on Integrase Inhibitors in Virologically Suppressed HIV-Infected Patients
Quick Look
High-Dose Baricitinib for Severe Alopecia Areata with Suboptimal Response to Conventional Therapy: A Real-World Assessment
Quick Look
Sugary Drinks and High-Fat Foods are Associated with Poor Treatment Response in Psoriasis: A Prospective Study in Shanghai
Quick Look
Response to: Intralesional measles, mumps, and rubella vaccine versus vitamin D for treatment of warts: A randomised clinical trial
Quick Look
Rapid Onset of Response in Adults with Dermatomyositis Receiving Dazukibart: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study
Quick Look
Impact of Hepatitis B and C Virus Infections on the Prognosis of Human Immunodeficiency Virus–Positive Patients Taking Antiretroviral Drugs: A Prospective Cohort Study at the Dormaa Presbyterian Hospital in the Bono Region of Ghana
Quick Look
Association Between Bimekizumab’s Clinical Response and Patient-Reported Benefits on Health-Related Quality of Life: Results from BE HEARD I and II
Quick Look
Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis)
Quick Look
A Response to: “Letter to the Editor Regarding ‘Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis’”